Drug Trial Radar · NCT07816185
A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
376
Planned (sponsor's estimate)
Start
Aug 31, 2026
Primary completion
Jan 28, 2029
Study completion Aug 31, 2029
Sponsor
- Lead sponsor
- Pulmovant, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
Conditions
- Pulmonary Hypertension
- Interstitial Lung Disease
- Vascular Diseases
- Cardiovascular Diseases
- Fibrosis
Interventions
MosliciguatDrug
Dose level 1, 2, or 3 for inhalation
PlaceboDrug
Matching Placebo for inhalation
Dry Powder InhalerDevice
Administration via dry powder inhaler
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in 6-Minute Walk Distance (6MWD)Time frame: Baseline to Week 24
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Clinical Research Site
Kissimmee, Florida · Recruiting
Clinical Research Site
Louisville, Kentucky · Recruiting
Clinical Research Site
Bend, Oregon · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.